EA201490746A2 - Применение прогестерона при профилактике и после острого периода для улучшения исходов, связанных с сотрясением мозга - Google Patents

Применение прогестерона при профилактике и после острого периода для улучшения исходов, связанных с сотрясением мозга

Info

Publication number
EA201490746A2
EA201490746A2 EA201490746A EA201490746A EA201490746A2 EA 201490746 A2 EA201490746 A2 EA 201490746A2 EA 201490746 A EA201490746 A EA 201490746A EA 201490746 A EA201490746 A EA 201490746A EA 201490746 A2 EA201490746 A2 EA 201490746A2
Authority
EA
Eurasian Patent Office
Prior art keywords
progesteron
convergence
brain
prevention
improve
Prior art date
Application number
EA201490746A
Other languages
English (en)
Other versions
EA201490746A3 (ru
Inventor
Джейкоб В. Ванлэндингэм
Джон Субер
Майкл Левандовски
Original Assignee
Флорида Стейт Юниверсити Рисеч Фондэйшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Флорида Стейт Юниверсити Рисеч Фондэйшн filed Critical Флорида Стейт Юниверсити Рисеч Фондэйшн
Publication of EA201490746A2 publication Critical patent/EA201490746A2/ru
Publication of EA201490746A3 publication Critical patent/EA201490746A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Описаны композиции и способы для лечения черепно-мозговой травмы (ЧМТ) и легкой черепно-мозговой травмы (лЧМТ) с применением прогестерона и энантиомера прогестерона.
EA201490746A 2011-10-07 2012-10-05 Применение прогестерона при профилактике и после острого периода для улучшения исходов, связанных с сотрясением мозга EA201490746A3 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161544502P 2011-10-07 2011-10-07
US13/645,854 US20130090315A1 (en) 2011-10-07 2012-10-05 Prophylactic and post-acute use of progesterone to better outcomes associated with concussion
PCT/US2012/059030 WO2013052849A2 (en) 2011-10-07 2012-10-05 Prophylactic and post-acute use of progesterone to better outcomes associated with concussion

Publications (2)

Publication Number Publication Date
EA201490746A2 true EA201490746A2 (ru) 2015-11-30
EA201490746A3 EA201490746A3 (ru) 2016-09-30

Family

ID=48042460

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490746A EA201490746A3 (ru) 2011-10-07 2012-10-05 Применение прогестерона при профилактике и после острого периода для улучшения исходов, связанных с сотрясением мозга

Country Status (13)

Country Link
US (3) US20130090315A1 (ru)
EP (1) EP2763679A4 (ru)
JP (1) JP2014528457A (ru)
KR (1) KR20140098741A (ru)
CN (1) CN104010644A (ru)
AU (1) AU2012318391A1 (ru)
BR (1) BR112014008328A2 (ru)
CA (1) CA2851424A1 (ru)
EA (1) EA201490746A3 (ru)
IL (1) IL231981A0 (ru)
MX (1) MX2014004202A (ru)
WO (3) WO2013052849A2 (ru)
ZA (1) ZA201403266B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013052849A2 (en) * 2011-10-07 2013-04-11 Florida State University Research Foundation Prophylactic and post-acute use of progesterone to better outcomes associated with concussion
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MA39126B1 (fr) * 2013-12-20 2020-03-31 Prevacus Inc Synthèse d'enantiomère de progestérone et d'intermédiaires de celui-ci
ES2878405T3 (es) * 2014-02-04 2021-11-18 Bioscience Pharma Partners Llc Uso de inhibidores de flap para reducir la lesión mediada por neuroinflamación en el sistema nervioso central
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
US10314911B2 (en) 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US20180050005A1 (en) * 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
US11497754B2 (en) 2019-02-05 2022-11-15 Washington University Neurosteroids and enantiomers thereof for the prevention and treatment of neurodegenerative conditions
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383993A (en) 1980-05-30 1983-05-17 University Of Kentucky Research Foundation Nasal dosage forms containing natural female sex hormones
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
NL8801670A (nl) * 1988-07-01 1990-02-01 Walter Adrianus Josephus Johan Farmaceutisch preparaat.
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
FR2784584B1 (fr) * 1998-10-14 2002-09-20 Adir Procede de preparation d'une solution pour pulverisation nasale contenant une ou plusieurs hormones sexuelles et une cyclodextrine
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
US7029657B2 (en) 2002-08-02 2006-04-18 Balance Pharmaceuticals, Inc. Nasal spray steroid formulation and method
CN1517091A (zh) * 2003-01-16 2004-08-04 董英杰 黄体酮制剂及制备方法
FR2851470B1 (fr) * 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
CA2716095C (en) * 2008-02-26 2017-02-07 Emory University Steroid analogues for neuroprotection
CN101444520A (zh) * 2008-12-04 2009-06-03 严伟琪 黄体酮在制备治疗重症脑中风和脑损伤的药物中的应用
AU2010286450A1 (en) * 2009-08-31 2012-04-12 Eric B. Schneider Treatment and prevention of secondary injury after trauma or damage to the central nervous system
WO2013052849A2 (en) * 2011-10-07 2013-04-11 Florida State University Research Foundation Prophylactic and post-acute use of progesterone to better outcomes associated with concussion

Also Published As

Publication number Publication date
US20130090316A1 (en) 2013-04-11
US20130090317A1 (en) 2013-04-11
WO2013052889A1 (en) 2013-04-11
WO2013052885A2 (en) 2013-04-11
WO2013052849A2 (en) 2013-04-11
EP2763679A4 (en) 2016-06-01
AU2012318391A1 (en) 2014-05-15
EP2763679A2 (en) 2014-08-13
IL231981A0 (en) 2014-05-28
JP2014528457A (ja) 2014-10-27
ZA201403266B (en) 2015-12-23
CA2851424A1 (en) 2013-04-11
WO2013052885A9 (en) 2013-09-26
MX2014004202A (es) 2015-03-05
CN104010644A (zh) 2014-08-27
US20130090315A1 (en) 2013-04-11
BR112014008328A2 (pt) 2017-04-18
AU2012318391A2 (en) 2014-12-04
US8492368B2 (en) 2013-07-23
EA201490746A3 (ru) 2016-09-30
KR20140098741A (ko) 2014-08-08

Similar Documents

Publication Publication Date Title
EA201490746A2 (ru) Применение прогестерона при профилактике и после острого периода для улучшения исходов, связанных с сотрясением мозга
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201490546A1 (ru) Замещенные аннелированные пиримидины и их применение
EA201491339A1 (ru) Замещенные аннеллированные пиримидины и триазины и их применение
AU2011328009A8 (en) Compounds and methods for treating pain
MX2022004300A (es) Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas.
RU2018145985A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
MX362185B (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
UA113627C2 (xx) Кристалічна форма циклоспорину a, фармацевтична композиція та спосіб лікування
MX2018008882A (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
SG10201804034QA (en) Methods for treating hypotension
EA201990403A1 (ru) Человеческие анти-vegfr-2/kdr-антитела
EA201391702A1 (ru) Интраназальные тестостероновые составы с пониженной дозировкой в виде геля и их применение для лечения аноргазмии или гипоактивного расстройства сексуального желания
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
WO2015084883A3 (en) Compositions and methods for treating osteoarthritis
MX2015005111A (es) Composicion a base de hierbas para la prevencion y tratamieto de tnf-a una enfermedad mediada.
MX2016002308A (es) Tratamiento del mieloma multiple.
EA201071350A1 (ru) Композиции и способы для лечения воспаления роговицы
MX2016002307A (es) Tratamiento para el cancer.
EA201500143A1 (ru) Терапия макулярной дегенерации на основе баклофена и акампросата
MX2015001695A (es) Regimenes de tratamiento.
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
EA201301080A1 (ru) Применение солей 3-карбокси-n-этил-n,n-диметилпропан-1-аммония при лечении сердечно-сосудистого заболевания